This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Comparative agents: Norepinephrine
Indication: Treatment of neurogenic orthostatic hypotension
Mechanism of action:
Synthetic amino acid analog that is metabolized to norepinephrine by dopa-decarboxylase. The increased levels of norepinephrine produce increase peripheral arterial and venous vasoconstriction. 
Metreleptin -Myalept (AstraZeneca)

Comparative agents: None
Indication:
Treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy
Mechanism of action:
Binding to and activating the human leptin receptor (ObR), which belongs to the Class I cytokine family of receptors that signals through the JAK/STAT transduction pathway; also appears to increase insulin sensitivity and reduce food intake Approved for use in people with cystic fibrosis with the following nine mutations: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, and G1349D Volume 49, May 2014 Deficiencies in the manufacturing facilities need to be addressed.
Recommended for NON-approval by an FDA advisory panel
Epinephrine
Primatene HFA Inhaler (Armstrong Pharmaceuticals)
Advisory panel voted against (18-6-1) approval as an over-the-counter (OTC) treatment for mild symptoms of intermittent asthma for people aged 12 and over. The vote was favorable for efficacy (14-10-1) and against its safety as an OTC agent (7-17-1). Doripenem is effective for its approved indications for the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including kidney infections (pyelonephritis). It is not approved for the treatment of any type of pneumonia. Compared to imipenem and cilastatin for injection, the use of doripenem in the treatment of pneumonia using ventilators is associated with an increased risk of death and lower clinical cure rates. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ ucm388328.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
